GlassScriptPhysician profile
Leon S Gedeon
NPI 1962727917
$1,156.69
in general payments reported to CMS, 2019-2025
15 companies · $411 in 2025
The $411 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $179 · 2022: $33.70 · 2023: $166 · 2024: $367 · 2025: $411.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $944.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $944.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $317.73 | 2019-2024 | Watchman Flx |
| Exact Sciences Corporation | $118.45 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Astrazeneca Pharmaceuticals LP | $107.48 | 2025 | Airsupra |
| Intuitive Surgical, INC. | $93.62 | 2024 | |
| Novo Nordisk INC | $92.59 | 2024-2025 | Wegovy |
| Gilead Sciences, INC. | $88.87 | 2019 | |
| Lilly USA, LLC | $82.14 | 2024-2025 | Zepbound, Mounjaro |
| Biosense Webster, INC. | $79.20 | 2025 | Carto 3, Nuvision Ice Catheter |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $40.92 | 2024-2025 | Xifaxan |
| Phathom Pharmaceuticals, INC. | $33.25 | 2024 | Voquezna |
| Shield Therapeutics INC | $31.88 | 2024 | |
| Pfizer INC. | $19.55 | 2023 | |
| Xeris Pharmaceuticals, INC. | $19.26 | 2022 | |
| Amgen INC. | $17.31 | 2025 | Otezla, Repatha |
| Novartis Pharmaceuticals Corporation | $14.44 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Leon Gedeon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.